VESPER: Stress Urinary Incontinence STUDY

计划入组 30 人 · 首次发布于 2019 年 6 月 24 日

VESPER: Pelvic Organ Prolapse Study

计划入组 25 人 · 首次发布于 2019 年 6 月 24 日

A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)

计划入组 180 人 · 首次发布于 2026 年 8 月 31 日

Hepatitis(Biomics Biotechnologies)

NB1000S(Novome Biotechnologies)

X-linked hypophosphatemic rickets therapeutic agents (Osta Biotechnologies)

Vesper Biotechnologies ApS

Denmark

Vesper Medical, Inc.

United States

ADVERUM BIOTECHNOLOGIES INC.

United States

Brazil Rises to 2nd Worldwide in Clinical Trial Recruitment, Driven by Execution and Population Diversity

Vesper Bio's VES001 Shows Promise in Phase I Trial for Frontotemporal Dementia

VESPER Trial: BaSq Subtype Linked to Poorer Outcomes in Bladder Cancer